Enlivex Therapeutics announced positive interim six-month data from its Phase I/II Allocetra™ trial for knee osteoarthritis. The trial showed statistically significant reductions in pain and improvements in joint function, with a sustained response at six months and no serious adverse events. The company will host a webinar on March 5, 2025, to discuss these results.
This positive data is a significant development in the osteoarthritis treatment landscape. Current treatments often provide limited pain relief and can have significant side effects. Allocetra™’s potential for sustained efficacy and safety could address a substantial unmet need for a long-term, effective therapy for this debilitating condition, offering hope for improved quality of life to millions of patients. This positive data may also spur further investment and research into macrophage reprogramming therapies, potentially opening new avenues for treating other inflammatory conditions.
Interim results from the Phase I stage show a 47% average pain reduction (P=0.0001) and a 46% improvement in joint function six months post-treatment. Furthermore, 83% of patients maintained a positive response to treatment at the six-month mark. Importantly, no serious adverse events were observed.
These positive interim results suggest Allocetra™ may become a viable treatment option for moderate to severe knee osteoarthritis. The sustained efficacy and favorable safety profile position Enlivex to potentially advance to the next phase of clinical trials and eventually bring a much-needed new therapy to market. This could significantly impact both Enlivex and the broader osteoarthritis treatment landscape.
Source link: \
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
